Mount Sinai Launches TWILIGHT: Is Ticagrelor Alone Superior to DAPT Post-PCI?

Today Mount Sinai Medical Center in New York announced the launch of a new and very large randomized clinical trial to test the safety and efficacy of ticagrelor alone versus ticagrelor and aspirin together in high risk PCI patients. The international study, called TWILIGHT, aims to enroll 9,000 patients at 100 sites in the U.S., Canada, Europe, South America, and Asia. The study is being funded by AstraZeneca, the manufacturer of the blood-thinner ticagrelor (brand name Brilinta).

http://www.ptca.org/news/2015/0811_TWILIGHT.html

Source: News from Angioplasty.Org - August 12, 2015 Category: Cardiology Source Type: news